UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION IV
1600 EAST LAMAR BLVD
ARLINGTON, TEXAS 76011-4511

EMAIL

Name:	Alan Skolnick, M.D.	License: 50-29111-01
Organization:	Alaska Heart Institute, LLC dba Alaska Heart & Vascular Institute	Docket: 030-34474 Control: 592142
Phone:	907-561-3211	
E-mail Address:	askolnick@alaskaheart.com	
From:	Jacqueline D. Cook	
Date:	December 24, 2016	
Subject:	Letter dated September 26, 2016 for License Amendment	
Pages:	2	

Dr. Skolnick:

Per your letter dated September 26, 2016, the item on the next page is a request for additional information which requires your response. **Please respond to this e-mail by Tuesday, January 17, 2016.** Our fax number is (817) 200-1263. Please provide a response in a signed and dated letter in pdf format when responding via email. My email address is Jackie.Cook@nrc.gov. When responding to this e-mail, please include the license, docket, and control numbers located at the top of this page.

Thanking you in advance for your cooperation, assistance, and prompt response in this matter.

/RA/
Jacqueline D. Cook
Senior Health Physicist

PUBLIC
☐ Immediate Release
☑ Normal Release

NON-PUBLIC
☐ A.3 Sensitive-Security Related
☐ A.7 Sensitive Internal
☐ Other:_____

Reviewer: JDC Date: 12/24/16

1. In your letter dated September 26, 2016, you are requesting an amendment to your license to change the suite number in license condition 10.A.

   Please give the reason for this change (i.e., typographical error, you physically changed suites, etc.).

   If you physically changed suite numbers, please provide a facility diagram to include the following:

   - Drawings should be to scale, and the scale used should be indicated;
   - Location, room numbers, and principal use of each room or area where byproduct material is prepared, used or stored; location of direct transfer delivery tubes from a PET radionuclide/radioactive drug production facility, or production area of PET radioactive drugs under 10 CFR 30.32(j), as provided above under the heading "Discussion" in Section 8.16 Item 9: Facility Diagram of NUREG-1556, Vol. 9, Rev. 2 (https://www.nrc.gov/reading-rm/doc-collections/nuregs/staff/sr1556/v9/) ; and areas where higher energy gamma-emitting radionuclides (e.g., PET radionuclides) are used, including a "quiet room", if applicable;
   - Location, room numbers, and principal use of each adjacent room (e.g., office, file, toilet, closet, hallway), including areas above, beside, and below therapy treatment rooms, indicating whether the room is a restricted or unrestricted area as defined in 10 CFR 20.1003; and
   - Shielding calculations, including information about the type, thickness, and density of any necessary shielding to enable independent verification of shielding calculations, and a description of any portable shields used (e.g., shielding of proposed patient rooms used for implant therapy, including the dimensions of any portable shield, if one is used; source storage safe; shielding for PET radionuclide direct transfer tubes; PET radioactive drug production areas).